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Original Article

Impact of honey on radiotherapy-induced oral mucositis in
patients with head and neck cancer: a systematic review and
meta-analysis
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Background: Oral mucositis is one of the most frequent, irreversible and distressing complications faced
by head and neck cancer (HNC) patients undergoing radiotherapy. Several studies have investigated the role
of honey in the prevention and alleviation of radiation-induced oral mucositis in HNC patients, however, a
definitive conclusion has not yet been generated. We performed this updated systematic review and metaanalysis to determine whether honey can prevent and alleviate radiation-induced oral mucositis in HNC
patients.
Methods: We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL)
and China National Knowledge Infrastructure (CNKI) through October 2019. We searched and selected
literature, extracted data and assessed risk of bias accordingly, and then conducted statistical analyses with
RevMan software version 5.3.
Results: Seven trials involving 412 patients were included in the final analysis. Meta-analyses showed that
honey did not decrease the incidence of radiation-induced oral mucositis [(relative risk (RR), 0.69; 95%
confidence interval (CI), 0.40–1.18; P=0.18]; however, relieved the severity of oral mucositis (RR, 0.22;
95% CI, 0.13–0.38; P<0.001), maintained or increased weight (RR, 1.92; 95% CI, 1.33–2.77; P<0.001)
and reduced the treatment interruption related to oral mucositis (RR, 0.13; 95% CI, 0.02–0.97; P=0.05).
Qualitative analysis also revealed a decreased incidence of oral mucositis in the honey group.
Conclusions: Based on limited evidence, honey may have a clinical benefit against radiation-induced oral
mucositis in HNC patients. However, future trials with large-scale and rigorous methods are warranted to
further establish the role of honey in the management of radiation-induced oral mucositis.
Keywords: Head and neck cancer; radiotherapy; oral mucositis; honey; meta-analysis
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Introduction
Head and neck cancers (HNC) are the sixth most common
cancer around the world (1), with estimated new cases
of 710,000 in 2018 (2). Radiotherapy (RT) alone or in
combination with chemotherapy or surgery remains a
cornerstone in treating HNC (3). Unfortunately, RT also
damages epithelium and submucosal connective tissue
and then causes inflammation (4). Cancer patients will
experience oral mucositis when radiation destructed oral
mucosal integrity (5).
Oral mucositis has been emerging as the most frequent,
inevitable and distressing complication faced by HNC
patients treated with RT (6). Published studies revealed
that almost of all HNC patients undergoing RT would
experience oral mucositis (7). Evidence also suggested that
about half of HNC patients experience grade 3 and above
oral mucositis if exposure of the large mucosal surface to
66–70 Gy radiation in 6–7 weeks with 1.8–2 Gy per fraction
(8-10). Oral mucositis leads to pain, difficulty swallowing,
nutritional issues, increased risk of infection and treatment
interruption. It significantly impacts on patients' quality
of life (QoL) (11). In addition, severe mucositis prolongs
the hospital stay and increases medical expenditure (12).
Thus, it is critical to develop effective methods to prevent
and treat oral mucositis because the treatment interruption
jeopardizes the cancer-destroying effect of RT and
magnifies the chance of tumor cell repopulation (13).
Numerous pharmacological and non-pharmacological
interventions have been developed to treat radiationinduced oral mucositis (14), such as oral zinc sulfate (15)
and laser therapy (16). However, a definitive intervention
regime has not yet been established (17,18). Therefore,
it is essential to explore alternative agent. Honey is the
by-product of flower nectar and the upper aero-digestive
tract of the honeybee, which becomes concentrated by the
dehydration process inside the beehive (5). As an ancient
medicament, honey has been established effective in several
fields, such as burn wounds, oral infections and surgical
wound (19,20). To date, numerous clinical trials have been
designed to explore the role of honey in preventing and
treating radiation-induced oral mucositis in HNC patients.
Several systematic reviews and meta-analyses
comprehensively evaluated the efficacy of honey in the
management of radiation-induced oral mucositis (21-28).
However, most of these reviews did not distinguish between
RT and chemoradiotherapy. Out of these reviews, only one
published in 2013 specifically investigate the role of honey
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for managing oral mucositis in HNC patients who were
treated with RT alone (21). Regrettably the review included
two ineligible trials in which patients were treated with
combination regime of RT plus chemotherapy. Yarom et al.
performed a systematic review to summarize the available
evidence of natural agents in the prevention and treatment
of oral mucositis in cancer patients, and concluded no
guideline was possible (29). So, it remains unclear whether
honey use can prevent and treat oral mucositis in HNC
patients receiving RT. It is essential to investigate the efficacy
of honey in the management of radiation-induced oral
mucositis separately because the differences between RT
and chemotherapy cannot be ignored (30). We consequently
designed this updated systematic review and meta-analysis
to accurately determine the role of honey in the prevention
and treatment of radiation-induced oral mucositis in HNC
patients.
Methods
We performed the current systematic review and metaanalysis according to the criteria proposed by the Cochrane
Collaboration (CC) (31). We reported all results following
the framework issued in the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis (PRISMA)
statement (32).
Selection criteria
We designed the selection criteria in line with the previous
review (21), which was strongly associated with our topic:
(I) adult HNC patients undergoing RT alone; (II) patients
in the treatment group assigned to use honey and patients
in the control group took control regime or received no
treatment; (III) the incidence of severe oral mucositis (grade
3 and 4) was the primary outcome, and the incidence of
oral mucositis regardless of grade, incidence of weight
maintenance, incidence of treatment interruption and
honey-related adverse events were the secondary outcomes;
and (IV) clinical trials including clinical controlled trials
(CCTs) and randomized controlled trials (RCTs) were
considered to meet our criteria. Conference abstracts with
sufficient information were also considered to be eligible.
Language of trials was limited to English and Chinese.
A trial will be excluded if at least one of following criteria
was covered: (I) trial enrolled HNC patients who were
also treated with chemotherapy in addition to RT, (II) trial
provided insufficient information to enable a judgment, (III)
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trial enrolled patients who had undergoing oral mucositis
treatment previously, and (IV) poor methodology (assessed
by XT).

disagreement about inclusion and the extraction of the basic
information and data were resolved by consulting a third
author.

Definition of outcomes

Assessment of risk of bias

In the current study, the incidence of radiation-induced
oral mucositis was defined as the value of a number of oral
mucositis cases, irrespective of the grade, divided by the
total number of HNC patients completing the whole study.
The severity of oral mucositis was evaluated with a scoring
system released by the Radiation Therapy Oncology Group
(RTOG), World Health Organization (WHO) or the Oral
Mucositis Assessment Scale (OMAS) (25). Grade 3 or 4 is
considered intolerable or severe according to the established
scales (23). The incidence of weight maintenance and the
incidence of treatment interruption related to oral mucositis
was defined as the value of a number of static or positive
weight gain and study discontinuation divided by the total
number of cancer patients completing the whole study
respectively.

Two investigators were assigned to independently evaluate
the risk of bias from the following seven domains:
randomization sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome
assessors, incomplete outcome data, selective reporting,
and other biases using the Cochrane risk of bias assessment
tool (34). The overall quality of the methodology of an
individual study was rated according to the matched
level between the actual information and the evaluation
criteria (35). Any disagreements between two investigators
were addressed through consulting a third investigator.

Identification of eligible literature
Two investigators were assigned to independently
search all citations in four databases including PubMed,
EMBASE, Cochrane Central Register of Controlled
Trials (CENTRAL) and China National Knowledge
Infrastructure (CNKI) from its inception through October
2019. We also hand-checked the reference lists of all
eligible trials and topic-related reviews so that any potential
trial can be covered. Search strategies were constructed
by combining Medical Subject Headings (MeSH) and text
words according to the unique requirements of individual
database (33). The key terms used, including: honey,
radiation, and oral mucositis. We documented all search
strategies of English databases in the Supplementary File.
We used Endnote X7.0 software to manage all citations.
Data extraction
Two investigators were assigned to independently select the
eligible trials according to the selection criteria and extract
data from each eligible trial with standard sheet. In this
study, we extracted the information including first author,
publication year, country of leading author, sample size,
sex ratio, age of patients, details of intervention regimes,
details of radiation dosages, and outcomes of interest. Any
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Statistical analysis
In this review and meta-analysis, all outcomes were
dichotomous data, and thus we used risk ratio (RR) with
95% confidence interval (CI) to estimate it. We used a
random-effects model to calculate all estimates because
this model considering within and between studies’
heterogeneity simultaneously (36). We firstly adopted Q
statistic to describe the heterogeneity qualitatively (37). We
also used I2 statistic to quantitatively estimate the proportion
of the overall variation (38). For a single outcome, we drew
the funnel plot to qualitatively inspect the publication bias if
the accumulated number of included studies was more than
10 (39). We completed all statistical analyses with the
RevMan 5.3 (Copenhagen, Denmark: The Nordic Cochrane
Center, The Cochrane Collaboration, 2013).
Results
Identification and selection of eligible studies
We captured 144 items after initially searching for targeted
electronic databases. We removed 66 duplicats after running
‘Find Duplicates’ that is embedded in EndNote software.
We classified 13 records into potential inclusion file after
carefully reviewing the title and abstract of 78 items. We
retrieved full-texts of 13 records in order to check the
eligibility of each trial further. After excluding ineligible
trials according to the following reasons: conference
abstract (n=1), duplicates (n=1), and ineligible treatment
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Records identified through
database searching
(n=144)

Additional records identified
through other sources
(n=1)

Records after duplicates removed
(n=79)

Records screened
(n=14)

Records excluded
(n=65)

Full-text articles assessed for
eligibility
(n=7)

Studies included in qualitative
synthesis
(n=1)

Full-text articles excluded, with
reasons (n=7)
Conference abstract (n=1)
Duplicates (n=1)
Chemo-radiotherapy (n=5)

Studies included in quantitative
synthesis (meta-analysis)
(n=6)

Figure 1 Flow chart of identification and selection of eligible trials. Other sources refers to bibliography lists of eligible studies and topicrelated reviews.

regime (n=5), we included 1 (40) and 6 trials (5,41-45) in the
qualitative and quantitative analysis respectively. We drew
Figure 1 to depict the process of identification and selection
of eligible trials.

mucositis (5,41-45), and 2 reported weight maintenance and
treatment interruption related to oral mucositis (5,41). All
eligible trials reported that baseline information between
honey and control groups was not statistically significant.

Details of characteristics of all eligible trials

Assessment of risk of bias of single trial

We designed Table 1 to document details of characteristics
of all eligible trials. All studies (5,40-45) were published
between 2003 and 2017. The sample size of a single trial was
ranging from 40 to 82, with a median sample size of 60. All
trials used honey to prevent and treat radiation-induced oral
mucositis. However, control regimes in eligible trials were
different. Of 7 trials, 4 used normal saline (40,41,44,45),
1 used lignocaine gel (43), 1 used water mouthwash (42),
and 1 used standard protocol (5). Three trials used the
Radiation Therapy Oncology Group (RTOG) grading
system to evaluate the severity of oral mucositis (5,40,43),
3 used the World Health Organization (WHO) grading
system to assess the grade of oral mucositis (41,42,45),
and 1 used the Oral Mucositis Assessing Scale (OMAS)
to grade the severity of oral mucositis (44). Two trials
reported an incidence of radiation-induced oral mucositis
(5,41), 6 reported incidence of severe radiation-induced oral

We drew Figure 2 to show the details of the risk of
bias of an eligible single trial. Of included 7 trials, 5
reported the methods of generating random sequence
in detail such as computer-generated random numbers
and table of the random numbers (5,40-43). Only 1 trial
conducted allocation concealment (43). Two trials stated
the information of blinding investigator, participant and
assessor (43,44). Furthermore, two trials did not adopt blind
method (5,41). In summary, the overall level of quality of all
eligible trials was regarded as moderate.
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Meta-analysis of clinical outcomes
Incidence of oral mucositis
Of seven eligible trials, 2 involving 120 patients reported
the incidence of oral mucositis after the patients were
instructed to use honey (5,45). Meta-analysis revealed no
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40 (20/20)

40 (20/20)

NR

22 vs. 18

China

Su Q, 2015

HG

Intervention strategies
CG

20 mL
lignocaine gel

20 mL
normal saline

Using Equinox and Telecobalt
Theratron 780C machines at a
dose of 1.8–2 Gy 5 days in a
week

NR

NR

6-MV X-ray beams from linear
accelerator at a dose rate of 2 Gy
per day five times a week up to a
dose of 66 Gy

6,000 cGy of radiation over 6
weeks. Radiation would be given
once a day, for 5 days a week

Using Cobalt 60 at a dose of
1.8 to 2 Gy per day, five times a
week up to total dose of 50 to
60 Gy (in five to six weeks)

6-MV linear accelerator at a dose
rate of 2 Gy per day five times a
week up to a dose of 60–70 Gy

Details of RT regime

SRIOM

IRIOM,
ISRIOM

ISRIOM

ISRIOM,
WM, TI

ISRIOM

ISRIOM

IRIOM,
ISRIOM,
WM, TI

Outcomes

HG, honey group; CG, control group; M, male; F, female; RT, radiotherapy; IRIOM, incidence of radiation-induced oral mucositis; ISRIOM, incidence of severe
radiation-induced oral mucositis; WM, weight maintenance; TI, treatment interruption; NR, not reported.

50.17/49.90 20 mL Ziziphus honey 15 min before 20 mL normal
and after the radiotherapy from day saline
1 of radiation till the end of 6th week

20 mL normal
saline

water as
mouthwash

20 mL polyfloral honey 15 min before 20 mL normal
and after radiotherapy and 6 h later saline

20 mL polyfloral honey (Western
Ghats forests) 15 min before and
after radiotherapy and before going
to bed

(47.8±19.6)/ 50 mL polyfloral honey and 25 mL
(52.0±17.5) water, and administration schedule
not given

NR

NR

(57.05±9.43)/ 20 mL pure natural honey (thyme
(56.95±14.5) and astragale) 15 min before and
after RT and 6 h later

80 (40/40) (30/10)/(32/8) (46.52±14.18)/ 20 mL pure natural honey 15 min
(45.76±12.31) before and after RT and 6 h later

70 (35/35) (22/13)/(30/5)

Amanat A, 2017 Pakistan 82 (41/41) (27/14)/(33/8)

Iran

Bahramnezhad
F, 2015

Age (HG/CG)

(8/12)/(15/5) (14-78)/(19-89) 20 mL tea plant honey 15 min before Standard
and after RT and 6 h later
protocol

Sex (M/F)/
(HG/CG)

Pakistan 60 (30/30) (20/10)/(19/11)

India

Khanal B, 2010

Alvi ZA, 2013

Iran

Malaysia 40 (20/20)

Biswal BM,
2003

Motallebnejad
M, 2008

Country

Study

Sample Size
(HG/CG)

Table 1 Details of studies included in the present meta-analysis
Annals of Palliative Medicine, Vol 9, No 4 July 2020
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Weight maintenance
Two trials involving 100 patients, out of seven eligible trials,
reported weight maintenance (5,41). Meta-analysis revealed
a higher proportion of static or positive weight gain in
patients who were instructed to use honey compared to
patients were assigned in control group (two trials; RR, 1.92;
95% CI, 1.33–2.77; P<0.001, I2 =0%, Figure 3C).
Oral mucositis induced treatment interruption
Out of seven eligible trials, two reported the incidence of
oral mucositis induced treatment interruption (5,41). The
meta-analysis suggested a lower incidence of oral mucositis
induced treatment interruption in honey group (two trials;
RR, 0.13; 95% CI, 0.02–0.97; P=0.05, I2 =0%, Figure 3D).

Other bias

Selective reporting (reporting bias)

Incomplete outcome data (attrition bias)

value of Grade 3 mucositis: 0.016 and P value of Grade 4
mucositis: 0.032).
Blinding of outcome assessment (detection bias)

Blinding of participants and personnel (performance bias)

Allocation concealment (selection bias)

Random sequence generation (selection bias)

1436

Alvi ZA 2013
Amanat A 2017
Bahramnezhad F 2015

Honey related adverse events
For all eligible trials, no complications related to the
administration of honey were reported. Moreover, no report
of study discontinuation because of honey.

Biswal BM 2003
Khanal B 2010
Motallebnejad M 2008
Su Q 2015

Figure 2 Risk of bias summary. Green, yellow and red solid circle
represents low, unclear and high risk of bias respectively.

significant difference in the incidence of oral mucositis
between the honey and control groups (two trials; RR, 0.69;
95% CI, 0.40–1.18; P=0.18; I2 =81%; Figure 3A).
Incidence of severe oral mucositis
Among the seven eligible trials, six studies including 330
patients reported the incidence of severe oral mucositis
(5,41-45). Meta-analysis suggested that honey use was
associated with decreased incidence of severe oral mucositis
(six trials: RR, 0.22; 95% CI, 0.13–0.38; P <0.001, I2 =9%,
Figure 3B).
However, one study (40) reported the incidence of
severe oral mucositis lesions, which were inconsistent with
results in other trials. So, it was not incorporated into metaanalysis. However, we used descriptive analysis to clarify
the findings. This trial found that the incidence of severe
radiation-induced oral mucositis lesions in the honey
group was significantly lower than that in control group (P

© Annals of Palliative Medicine. All rights reserved.

Publication bias
In the present systematic review and meta-analysis, the
accumulated number of eligible trials for each outcome of
interesting were all less than ten. We therefore did not draw
a funnel plot to check potential publication bias.
Discussion
According to the latest data issued by the IARC, HNCs
remain the critical threat to publics around the world (2).
RT plays an important role in the comprehensive treatment
of HNCs (44). Although RT can effectively destroy cancer
cells, it also causes damage to healthy tissues located in the
radiation portals due to the cytotoxic effect (44). As the
most common acute complication of RT, oral mucositis
will occur after the mucous membrane integrality was
broken (46). Radiation-induced oral mucositis will cause
a series of adverse consequences such as pain, discomfort,
dysphagia, dehydration, micronutrient deficiency, weight
loss (41). To effectively prevent and treat this condition,
several intervention regimes have been developed (47).
However, an effective, safe and convenient regime is still
not established. It is, therefore, necessary to investigate the
value of other alternative regimes for the prevention and
treatment of radiation-induced oral mucositis in patients
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A

B

C

D

Figure 3 Meta-analysis of clinical outcomes. (A) incidence of oral mucositis, (B) incidence of severe oral mucositis, (C) incidence of weight
maintenance, and (D) incidence of treatment interruption. CI, confidence interval; M-H, Mantel Haenszel.

with HNC.
Honey has been used as a prophylactic or therapeutic
agent since ancient times (48). Experimental studies
suggested that honey has the potential of maintaining
integrity of cellular epithelium tissue, preventing the intercellular rupture and inhibiting bacterial growth because
of its high viscosity, acidic PH, hydrogen peroxide, high
osmolarity, and rich nutritional properties (43,49). According
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to the findings from several RCTs, honey can enhance
healing of minor burns compared with conventional methods
such as polyurethane dressings and silver sulfadiazine
dressing (48-52). In this review, we first elucidate the efficacy
and safety of honey to prevent and treat radiation-induced
oral mucositis in HNC patients. Our meta-analysis suggested
that honey could significantly decrease the incidence of
severe radiation-induced oral mucositis (RR, 0.22; 95%
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CI, 0.13–0.38; P<0.001). Moreover, our qualitative analysis
also suggested a decreased incidence of severe radiationinduced oral mucositis in the honey group (P value of Grade
3 mucositis: 0.016 and P value of Grade 4 mucositis: 0.032).
Additionally, the meta-analysis also found that honey did
significantly maintain the weight of patients with HNC
(RR, 1.92; 95% CI, 1.33–2.77; P<0.001) and decrease the
incidence of treatment interruption related to oral mucositis
(RR, 0.13; 95% CI, 0.02–0.97; P=0.05). Several confounding
factors such as baseline nutritional status were reported in
included studies. So the result of weight maintenance must
be cautiously interpreted.
To date, nine systematic reviews and meta-analyses have
been conducted to explore the role of honey in preventing
and treating radiation- or chemoradiation-induced oral
mucositis in cancers. However, a conclusive finding for HNC
patients has not yet been generated. Song and colleagues, in
2012, performed a systematic review and meta-analysis to
investigate the protective effects against radiation-induced
oral mucositis in HNC, and demonstrated that honey use
reduced the incidence of oral mucositis (25). This study
enrolled three eligible trials, however one out of three trials
recruited most patients receiving chemo-radiotherapy (53).
Thus, five potential trials were missed (40-42,44,45).
In 2013, a systematic review of five trials, performed by
Charalambous et al. investigating the effectiveness of honey
for the management of RT-induced oral mucositis in HNC
patients, and found a clinical benefit of honey to radiationinduced oral mucositis (21). Unfortunately, two trials
involved patients who were prescribed to the combination
treatment of RT and chemotherapy instead of RT alone
(53,54), and quantitative analysis was also not performed. As
a result, four eligible trials were not considered (40-42,45).
In 2015, Cho et al. conducted a meta-analysis of nine eligible
trials to explore the effects of honey on oral mucositis in
HNC patients. However, only three trials of prescribing
RT alone to patients were included. It is noted that this
review performed subgroup analysis to separately inveterate
the impact of honey on patients undergoing RT alone,
and revealed that honey had a significantly higher effect in
preventing moderate to severe mucositis (28). Unfortunately,
this study enrolled an ineligible trial which was published
in 2013 (41). In 2016, Co and colleagues performed a
meta-analysis of five trials to quantitatively investigate the
effect of honey on clinical outcomes among HNC patients
receiving RT (22). However, among the five trials, only four
prescribed RT. Furthermore, the review failed to capture
three potentially eligible trials (22). In the same year of
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the review published, Xu et al. designed a meta-analysis to
investigate the effects of honey on the management of radio/
chemotherapy-induced mucositis, and revealed that honey
could effectively reduce the incidence of oral mucositis (26).
Although the authors included seven trials in the final
analysis, only three enrolled patients receiving RT alone, and
regrettably, the other four trials were misleading (40-42,45).
Furthermore, the study enrolled a trial investigating essential
oils of manuka (Leptospermum scoparium) and kanuka
(Kunzea ericoides) rather than manuka or kanuka honey (55).
Yang et al. (2018) performed a network meta-analysis to
explore the comparative efficacy of various kinds of honey
for chemo/radiotherapy-induced oral mucositis (27).
Although this study included twenty-one trials and
designed several subgroup analyses according to the age
of patients, cancer type and treatment regime, it is still
difficult to determine the role of honey use in preventing
and treating RT-induced oral mucositis in HNCs because
of only eight trials focused on patients receiving RT or
chemo/radiotherapy. Liu and colleagues (2019) performed
a meta-analysis to investigate the impact of honey use
on radiochemotherapy-induced mucositis. In this study,
authors considered several cancer types such as HNCs, acute
lymphoblastic leukemia (2 trials) and acute myeloid leukemia
(1 trial). Moreover, it also enrolled 4 trials that participants
were pediatric patients with HNC. Another review of 17
trials performed by Münstedt and colleagues evaluated the
role of honey in the management of side effects of RT- or
radio/chemotherapy-induced oral mucositis (24). In this
study, the authors used a qualitative approach to summarize
all evidence. Unfortunately, however, trials prescribing
RT alone were not analyzed separately. Moreover, the
review failed to include one eligible trial published in the
Chinese language. In 2013, Yarom et al. on behalf of the
Mucositis Study Group of the Multinational Association of
Supportive Care in Cancer and International Society of Oral
Oncology (MASCC/ISOO) systematically documented the
evidence for the use of natural agents for the management
of oral mucositis and concluded that the available data
were insufficient to reach a consensus (29). Moreover, this
review considered an ineligible study that enrolled patients
receiving chemo-radiotherapy (53). Compare to these
reviews, the present study has two advantages. Firstly, seven
eligible trials were analyzed, and this enables robust and
reliable findings; secondly, our review only included trials
that were specifically focusing on patients receiving RT
alone. Thus, the risk of impairing the validity and reliability
of pooled results of honey for the efficacy and safety of oral
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mucositis was reduced.
In the present systematic review and meta-analysis,
we captured seven eligible trials with an accumulated
sample size of 412 patients to generate more robust pooled
results. However, some limitations of our study must be
acknowledged. Firstly, three instruments were used to grade
the severity of radiation-induced oral mucositis across trials;
this variation may impair the comparability of these results.
A consistent instrument, therefore, should be adopted in
future trials. Secondly, control regimes used in the included
trials were different including normal saline, lignocaine
gel, water and blank control. Inappropriate control regime
may increase the risk of performance bias and thus decrease
the reliability of findings. Therefore, we suggest using
a uniform control regime in future trials such as normal
saline. Thirdly, all analyzed trials focused on the clinical
outcomes such as incidence of intolerable radiation-induced
oral mucositis, however other outcomes from patients’
perspective such as quality of life were not investigated.
Therefore, more outcomes should be designed in future
trials. Fourthly, the sample size of individual eligible trial
was insufficient, and thus future trials with large scale and
rigorous methodology must be considered. Fifthly, our
review did not address confounding variables for analyzing
weight maintenance and treatment interruption related to
oral mucositis due to insufficient data. So the pooled results
for these outcomes should be cautiously interpreted. More
importantly, future trials should report detailedly baseline
variables. Sixthly, our review did not design subgroup
analysis according to the RT machines because sufficient
information cannot be extracted. We therefore suggest
future trials to describe the details of RT.
In conclusion, oral honey may have the potential of
relieving the severity of radiation-induced oral mucositis,
maintaining weight, and decreasing the incidence of
treatment interruption related to oral mucositis in patients
with HNC based on the limited evidence. Considering
limitations in all included trials, we suggest designing future
trials with large-scales and rigorous methods to further
establish the role of oral honey for radiation-induced oral
mucositis.
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Supplementary

Search strategies for English-language databases
Search strategy of PubMed
Search

#13

#12

#11

Query
Search (((((“Neoplasms”[Mesh]) OR ((((((((((((((Cancer[Title/Abstract]) OR Neoplasia[Title/Abstract]) OR Neoplasias[Title/Abstract])
OR Neoplasm[Title/Abstract]) OR Neoplasms[Title/Abstract]) OR Tumors[Title/Abstract]) OR Tumor[Title/Abstract]) OR
Cancers[Title/Abstract]) OR Malignancy[Title/Abstract]) OR Malignancies[Title/Abstract]) OR Malignant[Title/Abstract]) OR
Malignant Neoplasm[Title/Abstract]) OR Benign Neoplasms[Title/Abstract]) OR Benign Neoplasm[Title/Abstract]))) AND
((((“Radiation”[Mesh]) OR “Radiotherapy”[Mesh])) OR (((((((((((Radiation[Title/Abstract]) OR Radiotherapy[Title/Abstract]) OR
Radiotherapies[Title/Abstract]) OR Radiation Theray[Title/Abstract]) OR Radiation Therapies[Title/Abstract]) OR Radiation
Treatment[Title/Abstract]) OR Radiation Treatments[Title/Abstract]) OR Targeted Radiotherapies[Title/Abstract]) OR Targeted
Radiotherapy[Title/Abstract]) OR Targeted Radiation Therapy[Title/Abstract]) OR Targeted Radiation Therapies[Title/Abstract])))
AND ((((“Mucositis”[Mesh]) OR “Stomatitis”[Mesh])) OR ((((((((Mucositis[Title/Abstract]) OR Mucositides[Title/Abstract]) OR
Stomatitis[Title/Abstract]) OR Stomatitides[Title/Abstract]) OR Oral Mucositis[Title/Abstract]) OR Oral Mucositides[Title/Abstract])
OR Oromucositis[Title/Abstract]) OR Oromucositides[Title/Abstract]))) AND ((“Honey”[Mesh]) OR Honey[Title/Abstract])
Search (“Neoplasms”[Mesh]) OR ((((((((((((((Cancer[Title/Abstract]) OR Neoplasia[Title/Abstract]) OR Neoplasias[Title/Abstract]) OR
Neoplasm[Title/Abstract]) OR Neoplasms[Title/Abstract]) OR Tumors[Title/Abstract]) OR Tumor[Title/Abstract]) OR Cancers
[Title/Abstract]) OR Malignancy[Title/Abstract]) OR Malignancies[Title/Abstract]) OR Malignant[Title/Abstract]) OR Malignant
Neoplasm[Title/Abstract]) OR Benign Neoplasms[Title/Abstract]) OR Benign Neoplasm[Title/Abstract])
Search (((((((((((((Cancer[Title/Abstract]) OR Neoplasia[Title/Abstract]) OR Neoplasias[Title/Abstract]) OR Neoplasm[Title/Abstract])
OR Neoplasms[Title/Abstract]) OR Tumors[Title/Abstract]) OR Tumor[Title/Abstract]) OR Cancers[Title/Abstract]) OR
Malignancy[Title/Abstract]) OR Malignancies[Title/Abstract]) OR Malignant[Title/Abstract]) OR Malignant Neoplasm
[Title/Abstract]) OR Benign Neoplasms[Title/Abstract]) OR Benign Neoplasm[Title/Abstract]

#10

Search “Neoplasms”[Mesh]

#9

Search (“Honey”[Mesh]) OR Honey[Title/Abstract]

#8

Search Honey[Title/Abstract]

#7

Search “Honey”[Mesh]

#6

#5

#4
#3

#2
#1

Search (((“Radiation”[Mesh]) OR “Radiotherapy”[Mesh])) OR (((((((((((Radiation[Title/Abstract]) OR Radiotherapy[Title/Abstract])
OR Radiotherapies[Title/Abstract]) OR Radiation Theray[Title/Abstract]) OR Radiation Therapies[Title/Abstract]) OR Radiation
Treatment[Title/Abstract]) OR Radiation Treatments[Title/Abstract]) OR Targeted Radiotherapies[Title/Abstract]) OR Targeted
Radiotherapy[Title/Abstract]) OR Targeted Radiation Therapy[Title/Abstract]) OR Targeted Radiation Therapies[Title/Abstract])
Search ((((((((((Radiation[Title/Abstract]) OR Radiotherapy[Title/Abstract]) OR Radiotherapies[Title/Abstract]) OR Radiation
Theray[Title/Abstract]) OR Radiation Therapies[Title/Abstract]) OR Radiation Treatment[Title/Abstract]) OR Radiation
Treatments[Title/Abstract]) OR Targeted Radiotherapies[Title/Abstract]) OR Targeted Radiotherapy[Title/Abstract]) OR Targeted
Radiation Therapy[Title/Abstract]) OR Targeted Radiation Therapies[Title/Abstract]
Search (“Radiation”[Mesh]) OR “Radiotherapy”[Mesh]
Search (((“Mucositis”[Mesh]) OR “Stomatitis”[Mesh])) OR ((((((((Mucositis[Title/Abstract]) OR Mucositides[Title/Abstract]) OR
Stomatitis[Title/Abstract]) OR Stomatitides[Title/Abstract]) OR Oral Mucositis[Title/Abstract]) OR Oral Mucositides[Title/Abstract])
OR Oromucositis[Title/Abstract]) OR Oromucositides[Title/Abstract])
Search (((((((Mucositis[Title/Abstract]) OR Mucositides[Title/Abstract]) OR Stomatitis[Title/Abstract]) OR Stomatitides
[Title/Abstract]) OR Oral Mucositis[Title/Abstract]) OR Oral Mucositides[Title/Abstract]) OR Oromucositis[Title/Abstract]) OR
Oromucositides[Title/Abstract]
Search (“Mucositis”[Mesh]) OR “Stomatitis”[Mesh]

Search strategy of CENTRAL
Search Name: Honey for Oral mucositis
Last Saved: 19/10/2019 01:07:41
Comment:

ID
#1
#2
#3
#4
#5
#6
#7
#8
#9
#10
#11
#12
#13
#14
#15
#16

Search
("mucositis"):ti,ab,kw OR ("mucositides"):ti,ab,kw OR ("stomatitis"):ti,ab,kw OR ("stomatitides"):ti,ab,kw OR ("oral
mucositis"):ti,ab,kw (Word variations have been searched)
MeSH descriptor: [Stomatitis] explode all trees
MeSH descriptor: [Mucositis] explode all trees
#1 OR #2 OR #3
("radiation"):ti,ab,kw OR ("radiotherapy"):ti,ab,kw OR ("radiotherapies"):ti,ab,kw (Word variations have been
searched)
MeSH descriptor: [Radiation] explode all trees
MeSH descriptor: [Radiotherapy] explode all trees
#5 OR #6 OR #7
("cancer"):ti,ab,kw OR ("neoplasia"):ti,ab,kw OR ("neoplasm"):ti,ab,kw OR ("tumor"):ti,ab,kw OR
("malignancy"):ti,ab,kw (Word variations have been searched)
("malignant"):ti,ab,kw OR ("benign neoplasm"):ti,ab,kw OR ("malignant neoplasm"):ti,ab,kw (Word variations have
been searched)
MeSH descriptor: [Neoplasms] explode all trees
#9 OR #10 OR #11
("honey"):ti,ab,kw (Word variations have been searched)
MeSH descriptor: [Honey] explode all trees
#13 OR #14
#4 AND #8 AND #12 AND #15

Search strategy of Embase
Embase
Session Results
No. Query Results
#13. #3 AND #6 AND #9 AND #12
#12. #10 OR #11
#11. 'honey'/exp
#10. honey:ti,ab,kw
#9. #7 OR #8
#8. 'mucosa inflammation'/exp OR 'oral mucositis'/exp OR 'stomatitis'/exp
#7. mucositis:ti,ab,kw OR mucositides:ti,ab,kw OR stomatitis:ti,ab,kw OR stomatitides:ti,ab,kw OR 'oral
mucositis':ti,ab,kw OR 'oral mucositides':ti,ab,kw OR oromucositis:ti,ab,kw OR oromucositides:ti,ab,kw
#6. #4 OR #5
#5. 'radiation'/exp OR 'radiotherapy'/exp
#4. radiation:ti,ab,kw OR radiotherap*:ti,ab,kw OR 'radiation therapy':ti,ab,kw OR 'radiation therapies':ti,ab,kw OR
'radiation treatment':ti,ab,kw OR 'radiation treatments':ti,ab,kw OR 'targeted radiotherapies':ti,ab,kw OR 'targeted
radiotherapy':ti,ab,kw OR 'targeted radiation therapy':ti,ab,kw OR 'targeted radiation therapies':ti,ab,kw
#3. #1 OR #2
#2. 'malignant neoplasm'/exp OR 'neoplasm'/exp
#1. cancer*:ti,ab,kw OR neoplasia*:ti,ab,kw OR neoplasm*:ti,ab,kw OR tumor*:ti,ab,kw OR malignanc*:ti,ab,kw
OR malignant*:ti,ab,kw OR 'malignant neoplasm':ti,ab,kw OR 'malignant neoplasm*':ti,ab,kw OR 'benign
neoplasms':ti,ab,kw OR 'benign neoplasm':ti,ab,kw

